Bio-Rad & the University of Chicago Win Patent Infringement Case Against 10X Genomics Related to Droplet Microfluidics Techno...
November 14 2018 - 8:30AM
Business Wire
A Federal District Court jury yesterday found that 10X Genomics
willfully infringed three United States patents owned by the
University of Chicago and exclusively licensed to Bio-Rad
Laboratories, Inc., a global leader in life science research and
clinical diagnostics products (NYSE: BIO and BIOb). In awarding
Bio-Rad $23.9 million in damages, the jury unanimously found that
all Single Cell and Linked-Read genomics products sold by 10X
Genomics willfully infringed the patents owned by the University of
Chicago and licensed to Bio-Rad.
“We are obviously pleased with the outcome of the case,” said
Norman Schwartz, Bio-Rad President and Chief Executive Officer.
“Bio-Rad remains committed to growing and protecting its portfolio
of patents in the droplet microfluidics space and to delivering
differentiated genomics technologies that enable world class
research.”
In a separate earlier action before the International Trade
Commission, an administrative law judge made an initial
determination that certain microfluidic devices used by 10X in its
products infringe patent rights owned by Bio-Rad.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global
leader in developing, manufacturing, and marketing a broad range of
innovative products for the life science research and clinical
diagnostic markets. With a focus on quality and customer service
for over 65 years, our products advance the discovery process and
improve healthcare. Our customers are university and research
institutions, hospitals, public health and commercial laboratories,
biotechnology, pharmaceutical, as well as applied laboratories that
include food safety and environmental quality. Founded in 1952,
Bio-Rad is based in Hercules, California, and has a global network
of operations with more than 8,000 employees worldwide. Bio-Rad had
revenues exceeding $2.1 billion in 2017. For more information,
please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding Bio-Rad remaining
committed to growing and protecting its portfolio of patents in the
droplet microfluidics space and to delivering differentiated
genomics technologies that enable world class research.
Forward-looking statements generally can be identified by the use
of forward-looking terminology such as “commit”, “will,” “expect,”
“anticipate,” “plan,” “intend,” “estimate,” “believe,” or similar
expressions or the negative of those terms or expressions, although
not all forward-looking statements contain these words. Such
statements involve risks and uncertainties, which could cause
actual results to vary materially from those expressed in or
indicated by the forward-looking statements. These risks and
uncertainties include risks relating to intellectual property
rights, international legal and regulatory risks, our ability to
develop and market new or improved products, our ability to compete
effectively, and product quality and liability issues. For further
information regarding our risks and uncertainties, please refer to
the “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operation” in Bio-Rad’s public
reports filed with the Securities and Exchange Commission,
including our most recent Annual Report on Form 10-K and our
Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place
undue reliance on forward-looking statements, which reflect an
analysis only and speak only as of the date hereof. We disclaim any
obligation to update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181114005290/en/
Press Contact:Bio-Rad Laboratories, Inc.Tina Cuccia,
Corporate Communications510-724-7000tina_cuccia@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2023 to Apr 2024